^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EWSR1-POU5F1 fusion

    i
    Other names: EWSR1, EWS RNA Binding Protein 1, Ewing Sarcoma Breakpoint Region 1, RNA-Binding Protein EWS, EWS, Ewings Sarcoma EWS-Fli1 (Type 1) Oncogene, Ewing Sarcoma Breakpoint Region 1 Protein, EWS RNA-Binding Protein Variant 6, EWS Oncogene, BK984G1.4, EWS-FLI1, POU5F1, OCT4, POU Class 5 Homeobox 1, POU Domain, Class 5, Transcription Factor 1, Octamer-Binding Transcription Factor 3, Octamer-Binding Protein 3, Octamer-Binding Protein 4, OTF-3, Oct-3, Oct-4, OTF3, OCT3, OCT4, POU-Type Homeodomain-Containi
    Entrez ID:
    2130; 5460
    Related biomarkers:
    Expression
    Mutation
    Fusion
    1year
    Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. (PubMed, NPJ Precis Oncol)
    Median progression free survival was 3.84 months. Sapanisertib in combination with carboplatin plus paclitaxel demonstrated a manageable safety profile, with preliminary antitumor activity observed in advanced malignancies harboring mTOR pathway alterations.
    P1 data • Review • Journal
    |
    PTEN (Phosphatase and tensin homolog) • EWSR1 (EWS RNA Binding Protein 1) • POU5F1 (POU Class 5 Homeobox 1)
    |
    EWSR1-POU5F1 fusion
    |
    carboplatin • paclitaxel • sapanisertib (CB-228)
    2years
    Cytology-histology correlation of myoepithelial tumors harboring EWSR1-POU5F1 fusions: A report of two cases. (PubMed, Diagn Cytopathol)
    The cytomorphology of these tumors has not been well characterized. Reported here are the cytomorphologic features of two cases of EWSR1-POUF1-positive MET with histology correlation.
    Journal
    |
    EWSR1 (EWS RNA Binding Protein 1) • POU5F1 (POU Class 5 Homeobox 1)
    |
    MET positive • EWSR1-POU5F1 fusion